Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance

The emergence of antimicrobial-resistant (AMR) bacteria has become one of the most serious threats to global health, necessitating the development of novel antimicrobial strategies. CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) system, known as a bacterial adaptive immune system, can be repurposed to selectively target and destruct bacterial genomes other than invasive genetic elements. Thus, the CRISPR-Cas system offers an attractive option for the development of the next-generation antimicrobials to combat infectious diseases especially those caused by AMR pathogens. However, the application of CRISPR-Cas antimicrobials remains at a very preliminary stage and numerous obstacles await to be solved. In this mini-review, we summarize the development of using type I, type II, and type VI CRISPR-Cas antimicrobials to eradicate AMR pathogens and plasmids in the past a few years. We also discuss the most common challenges in applying CRISPR-Cas antimicrobials and potential solutions to overcome them.

• Publication year

  2021

• Venue

  Frontiers in Microbiology

• Publication date

  2021-08-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fmicb.2021.716064PMID 34489905PMCID 8418092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A transferrable and integrative type I-F Cascade for heterologous genome editing and transcription modulation

  2021cited by this paper
• CRISPR-Cas9 System

  2021cited by this paper
• Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis

  2021cited by this paper
• Formulation Strategies for Bacteriophages to Target Intracellular Bacterial Pathogens.

  2021cited by this paper
• Enlarging the Toolbox Against Antimicrobial Resistance: Aptamers and CRISPR-Cas

  2021cited by this paper
• Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies

  2020cited by this paper
• Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

  2020cited by this paper
• In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

  2020cited by this paper
• Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species

  2020cited by this paper
• A compact Cascade–Cas3 system for targeted genome engineering

  2020cited by this paper
• Rapid Detection of High-Level Tigecycline Resistance in Tet(X)-Producing Escherichia coli and Acinetobacter spp. Based on MALDI-TOF MS

  2020cited by this paper
• Molecular Mechanisms of CRISPR-Cas Immunity in Bacteria.

  2020cited by this paper
• Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes.

  2020cited by this paper
• How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance

  2020cited by this paper
• Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.

  2020cited by this paper
• Anti-CRISPR-Associated Proteins Are Crucial Repressors of Anti-CRISPR Transcription.

  2019cited by this paper
• Midbiotics: conjugative plasmids for genetic engineering of natural gut flora

  2019cited by this paper
• Eliminating mcr-1-harbouring plasmids in clinical isolates using the CRISPR/Cas9 system.

  2019cited by this paper
• The next generation of CRISPR–Cas technologies and applications

  2019cited by this paper
• Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants

  2019cited by this paper
• Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria

  2019cited by this paper
• Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant P. aeruginosa.

  2019cited by this paper
• Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci

  2019cited by this paper
• CRISPR-Cas antimicrobials: Challenges and future prospects

  2018cited by this paper
• Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model

  2018cited by this paper
• Temperature, by Controlling Growth Rate, Regulates CRISPR-Cas Activity in Pseudomonas aeruginosa

  2018cited by this paper
• Clinically Relevant Plasmid-Host Interactions Indicate that Transcriptional and Not Genomic Modifications Ameliorate Fitness Costs of Klebsiella pneumoniae Carbapenemase-Carrying Plasmids

  2018cited by this paper
• Discovery of widespread type I and type V CRISPR-Cas inhibitors

  2018cited by this paper
• Temperature effect on CRISPR-Cas9 mediated genome editing.

  2017cited by this paper
• Advances in Industrial Biotechnology Using CRISPR-Cas Systems.

  2017cited by this paper
• Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus

  2017cited by this paper
• Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance.

  2017cited by this paper
• Using CRISPR-Cas systems as antimicrobials.

  2017cited by this paper
• Capsids and Genomes of Jumbo-Sized Bacteriophages Reveal the Evolutionary Reach of the HK97 Fold

  2017cited by this paper
• Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

  2017cited by this paper
• Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane

  2017cited by this paper
• Mechanisms of Antibiotic Resistance

  2016cited by this paper
• CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases.

  2016cited by this paper
• Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?

  2016cited by this paper
• Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system

  2016cited by this paper
• C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

  2016cited by this paper
• Genetically Engineered Phages: a Review of Advances over the Last Decade

  2016cited by this paper
• Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection

  2016cited by this paper
• Harnessing heterologous and endogenous CRISPR-Cas machineries for efficient markerless genome editing in Clostridium

  2016cited by this paper
• Prophages mediate defense against phage infection through diverse mechanisms

  2016cited by this paper
• Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases

  2016cited by this paper
• A first step toward liposome-mediated intracellular bacteriophage therapy

  2015cited by this paper
• An updated evolutionary classification of CRISPR–Cas systems

  2015cited by this paper
• Bacteriophage-mediated spread of bacterial virulence genes.

  2015cited by this paper
• Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile

  2015cited by this paper
• Mechanisms of antibiotic resistance

  2015cited by this paper
• Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria

  2015cited by this paper
• Quality and Safety Requirements for Sustainable Phage Therapy Products

  2015cited by this paper
• Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.

  2015cited by this paper
• Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa

  2015cited by this paper
• CRISPR-Cas immunity in prokaryotes

  2015cited by this paper
• Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases

  2014cited by this paper
• Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system

  2014cited by this paper
• Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases

  2014cited by this paper
• Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems

  2014cited by this paper
• Mapping the Tail Fiber as the Receptor Binding Protein Responsible for Differential Host Specificity of Pseudomonas aeruginosa Bacteriophages PaP1 and JG004

  2013cited by this paper
• CRISPR-assisted editing of bacterial genomes

  2013cited by this paper
• Interaction of Bacteriophage λ with Its E. coli Receptor, LamB

  2012cited by this paper
• The Escherichia coli CRISPR System Protects from λ Lysogenization, Lysogens, and Prophage Induction

  2010cited by this paper
• Identification and characterization of E. coli CRISPR‐cas promoters and their silencing by H‐NS

  2010cited by this paper
• Extended-Spectrum β-Lactamases: a Clinical Update

  2005cited by this paper
• Identification of the Receptor-Binding Protein in 936-Species Lactococcal Bacteriophages

  2004cited by this paper
• Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens.

  2002cited by this paper

• Breaking resistance: strategies for novel antibacterial therapeutic interventions

  2026cites this paper
• Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions

  2026cites this paper
• CRISPR–Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance

  2026cites this paper
• Specific killing and resensitization of pathogenic Escherichia coli strains carrying blaCTX-M-15 β-lactamase using targeted-antibacterial-plasmids (TAPs)

  2026cites this paper
• Innovative biotherapeutics for antimicrobial resistance: From monoclonal antibodies to phage therapy

  2026cites this paper
• Spacio-Linear Screening for Ligand-Docking Cavities in Protein Structures: SLAM Algorithm.

  2026cites this paper
• Detection of carbapenem resistance among third-generation cephalosporin-resistant Enterobacterales from small-scale poultry farms in peri-urban Lusaka, Zambia

  2026cites this paper
• Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs

  2026cites this paper
• Functional characterization of a type I-F1 CRISPR-cas system from the clinical isolate Shewanella xiamenensis Sh95 reveals constitutive activity and plasmid-curing capability

  2026cites this paper
• Fluorescent Antibiotics: Bridging Diagnostic and Therapy in the Fight against Bacterial Infections

  2025cites this paper
• CRISPR-Cas Systems: Bridging Bacterial Immunity and Host Interactions

  2025cites this paper
• One‐pot assay for rapid detection of heterozygous herbicide resistance in Digitaria ciliaris var. chrysoblephara by combining CRISPR/Cas and LAMP

  2025cites this paper
• The Gut Microbiome and Colistin Resistance: A Hidden Driver of Antimicrobial Failure

  2025cites this paper
• Antibiotic resistance and preventive strategies in foodborne pathogenic bacteria: a comprehensive review

  2025cites this paper
• Frontiers in superbug management: innovating approaches to combat antimicrobial resistance

  2025cites this paper
• Emerging nano-vaccine technologies to overcome anti-microbial resistance.

  2025cites this paper
• Detection of antimicrobial resistance via state-of-the-art technologies versus conventional methods

  2025cites this paper
• A comprehensive review of advanced strategies to combat antimicrobial resistance

  2025cites this paper
• Integrative Strategies Against Multidrug-Resistant Bacteria: Synthesizing Novel Antimicrobial Frontiers for Global Health.

  2025cites this paper
• Mechanistic Basis of Multidrug Resistance: Current Status, Challenges, and Potential Solutions

  2025cites this paper
• Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector

  2025cites this paper
• Effective alternative strategies to combat challenges associated with MDR bacterial infections: Drug repurposing, role of artificial intelligence, and novel therapeutic options.

  2025cites this paper
• Breaking barriers in antimicrobial therapy: resistance mechanisms and novel antimicrobial strategies.

  2025cites this paper
• Advances in CRISPR-Cas systems for gut microbiome.

  2024cites this paper
• Precision Genome Editing Unveils a Breakthrough in Reversing Antibiotic Resistance: CRISPR/Cas9 Targeting of Multi-Drug Resistance Genes in Methicillin-Resistant Staphylococcus aureus

  2024cites this paper
• An insights into emerging trends to control the threats of antimicrobial resistance (AMR): an address to public health risks

  2024cites this paper
• Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR/Cas9-Based Genome-Editing to Combat This Health Emergency

  2024cites this paper
• CRISPR-Cas systems of lactic acid bacteria and applications in food science.

  2024cites this paper
• Possible Alternative Strategies to Combat Antimicrobial Resistance

  2024cites this paper
• CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance

  2024cites this paper
• Non-Canonical Aspects of Antibiotics and Antibiotic Resistance

  2024cites this paper
• Recent advances in gene-editing approaches for tackling antibiotic resistance threats: a review

  2024cites this paper
• CRISPR-Cas System, Antimicrobial Resistance, and Enterococcus Genus—A Complicated Relationship

  2024cites this paper
• Estrategias para el manejo de heridas crónicas complicadas con biopelícula de bacterias multirresistentes en equinos: revisión bibliográfica, diagnóstico y protocolo de tratamiento

  2024cites this paper
• Targeted Therapy for Intracellular Bacterial Pathogens

  2024cites this paper
• From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance—a review

  2024cites this paper
• CRISPR-Cas9-Mediated Targeting of Multidrug Resistance Genes in Methicillin-Resistant Staphylococcus aureus

  2024cites this paper
• A perspective on the role of the environment in the transmission of antibiotic resistance

  2024cites this paper
• CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions

  2024cites this paper
• Save the microbes to save the planet. A call to action of the International Union of the Microbiological Societies (IUMS)

  2023cites this paper
• Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers

  2023cites this paper
• The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases-Challenges and Opportunities.

  2023cites this paper
• Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

  2023cites this paper
• Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

  2023cites this paper
• CRISPR-Based Gene Editing in Acinetobacter baumannii to Combat Antimicrobial Resistance

  2023cites this paper
• Integrons as the potential targets for combating multidrug resistance in Enterobacteriaceae using CRISPR- Cas9 technique.

  2023cites this paper
• CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance

  2023cites this paper
• Repurposing prokaryotic clustered regularly interspaced short palindromic repeats-Cas adaptive immune system to combat antimicrobial resistance.

  2023cites this paper
• Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases

  2022cites this paper
• Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics

  2022cites this paper
• Novel configurations of type I-E CRISPR-Cas system in Corynebacterium striatum clinical isolates

  2022cites this paper
• Investigating the Genomic Background of CRISPR-Cas Genomes for CRISPR-Based Antimicrobials

  2022cites this paper
• Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System

  2022cites this paper
• In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials

  2022cites this paper
• Antibiotic stewardship in the era of precision medicine

  2022cites this paper
• CRISPR-Cas in diagnostics and therapy of infectious diseases.

  2022cites this paper
• Mobile Genetic Elements of Prokaryotes and Their Role in the Formation of Antibiotic Resistance in Pathogenic Bacteria

  2022cites this paper
• A Comprehensive Review: CRISPR-Cas9 and dCas9 Strategies in Mitigating Antimicrobial Resistance in Staphylococcus aureus

  year unknowncites this paper
• Harnessing the Immune System in the Fight Against Bacterial Infections: Current Strategies and Future Prospects

  year unknowncites this paper